









Markets
/
Stocks
/
nasdaq-podd
/

Insulet Corp

PODD

241.930USD

-1.220-0.50%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

17.02BMarket Cap

69.05P/E TTM



Insulet Corp

241.930

-1.220-0.50%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Insulet Corp

Currency: USD Updated: 2026-02-06

Key Insights

Insulet Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 46 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 371.57.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Insulet Corp's Score

Industry at a Glance

Industry Ranking

46 / 205

Overall Ranking

136 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Insulet Corp Highlights

StrengthsRisks

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 58.71% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.07B.

Fairly Valued

The company’s latest PE is 69.05, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 71.88M shares, decreasing 4.34% quarter-over-quarter.

Held by Mairs and Power

Star Investor Mairs and Power holds 1.13K shares of this stock.

Analyst Rating

Based on 28 analysts

Buy

Current Rating

371.565

Target Price

+52.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Insulet Corp is 8.97, ranking 22 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 706.30M, representing a year-over-year increase of 29.86%, while its net profit experienced a year-over-year increase of 13.03%.

Score

Industry at a Glance

Previous score

8.97

Change



Financials

9.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.65

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.48

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.65

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Insulet Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Insulet Corp is 3.60, ranking 201 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 69.05, which is 68908.81% below the recent high of 47652.24 and 53.72% above the recent low of 31.96.

Score

Industry at a Glance

Previous score

3.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 46/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Insulet Corp is 8.50, ranking 24 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 380.00, with a high of 432.00 and a low of 316.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 28 analysts

Buy

Current Rating

371.565

Target Price

+52.81%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Insulet Corp

PODD

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Insulet Corp is 6.57, ranking 126 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 277.30 and the support level at 223.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.54

Change

0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-4.577

Sell

RSI(14)

20.572

Sell

STOCH(KDJ)(9,3,3)

6.262

Oversold

ATR(14)

8.811

High Vlolatility

CCI(14)

-121.557

Sell

Williams %R

96.118

Oversold

TRIX(12,20)

-0.598

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

248.832

Sell

MA10

254.949

Sell

MA20

268.657

Sell

MA50

285.951

Sell

MA100

304.057

Sell

MA200

304.912

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Insulet Corp is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 102.17%, representing a quarter-over-quarter decrease of 0.21%. The largest institutional shareholder is The Vanguard, holding a total of 8.67M shares, representing 12.32% of shares outstanding, with 0.37% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

8.76M

+1.00%

Fidelity Management & Research Company LLC

6.91M

+0.85%

Capital Research Global Investors

4.55M

-3.95%

BlackRock Institutional Trust Company, N.A.

4.43M

+1.72%

State Street Investment Management (US)

3.09M

+1.11%

Baillie Gifford & Co.

Star Investors

2.09M

-2.03%

Geode Capital Management, L.L.C.

1.97M

+1.96%

ClearBridge Investments, LLC

1.47M

-4.52%

American Century Investment Management, Inc.

1.41M

+7.42%

Fidelity International

1.11M

-1.69%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Insulet Corp is 7.62, ranking 36 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.42. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.